Akari Therapeutics (AKTX) Competitors $1.18 +0.03 (+2.16%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. CGEN, ALEC, GALT, ACOG, IKT, ALTS, KYTX, RAPT, LXEO, and BDTXShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), ALT5 Sigma (ALTS), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), Lexeo Therapeutics (LXEO), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Compugen Alector Galectin Therapeutics Alpha Cognition Inhibikase Therapeutics ALT5 Sigma Kyverna Therapeutics Rapt Therapeutics Lexeo Therapeutics Black Diamond Therapeutics Compugen (NASDAQ:CGEN) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk. Does the media prefer CGEN or AKTX? In the previous week, Akari Therapeutics had 2 more articles in the media than Compugen. MarketBeat recorded 2 mentions for Akari Therapeutics and 0 mentions for Compugen. Akari Therapeutics' average media sentiment score of 0.32 beat Compugen's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Compugen Neutral Akari Therapeutics Neutral Which has more risk and volatility, CGEN or AKTX? Compugen has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Do institutionals and insiders believe in CGEN or AKTX? 12.2% of Compugen shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer CGEN or AKTX? Compugen presently has a consensus price target of $4.00, indicating a potential upside of 124.72%. Given Compugen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Compugen is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CGEN or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Compugen's net margin of -51.27%. Compugen's return on equity of -24.51% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen-51.27% -24.51% -12.19% Akari Therapeutics N/A -213.59%-65.60% Which has preferable earnings and valuation, CGEN or AKTX? Compugen has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M5.70-$14.23M-$0.16-11.13Akari TherapeuticsN/AN/A-$19.79MN/AN/A SummaryCompugen beats Akari Therapeutics on 9 of the 13 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.97M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A21.7127.6620.25Price / SalesN/A281.11416.07118.18Price / CashN/A42.7336.8958.07Price / Book1.407.518.035.67Net Income-$19.79M-$55.14M$3.18B$249.21M7 Day Performance1.80%4.61%2.92%3.28%1 Month Performance-9.92%4.72%3.72%5.55%1 Year Performance-58.89%5.92%35.14%21.08% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics1.5441 of 5 stars$1.18+2.2%N/A-62.9%$37.97MN/A0.009CGENCompugen1.5703 of 5 stars$1.78+7.2%$4.00+124.7%+6.6%$148.13M$27.86M-11.1370Positive NewsALECAlector3.7452 of 5 stars$1.40-5.4%$4.00+185.7%-66.6%$147.99M$100.56M-1.11270GALTGalectin Therapeutics1.6611 of 5 stars$2.11-9.4%$6.00+184.4%+0.2%$147.47MN/A-2.939ACOGAlpha Cognition1.7599 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/ANews CoveragePositive NewsIKTInhibikase Therapeutics1.3731 of 5 stars$1.95+20.4%$6.50+233.3%+64.3%$144.97M$260K-0.736News CoverageALTSALT5 Sigma0.118 of 5 stars$7.24-10.9%N/AN/A$141.91M$12.53M0.00170News CoverageKYTXKyverna Therapeutics1.7319 of 5 stars$3.07-6.4%$18.50+502.6%-62.3%$141.76M$7.03M-0.9196RAPTRapt Therapeutics4.2586 of 5 stars$8.00-5.1%$24.00+200.0%-62.7%$139.40M$1.53M-0.4280LXEOLexeo Therapeutics1.9109 of 5 stars$4.02-2.4%$16.60+312.9%-70.2%$136.77M$650K-1.2258BDTXBlack Diamond Therapeutics3.2955 of 5 stars$2.48+5.5%$14.60+488.7%-41.9%$133.63MN/A41.3390Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies Compugen Competitors Alector Competitors Galectin Therapeutics Competitors Alpha Cognition Competitors Inhibikase Therapeutics Competitors ALT5 Sigma Competitors Kyverna Therapeutics Competitors Rapt Therapeutics Competitors Lexeo Therapeutics Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
